Published in CMAJ Open on May 07, 2014
The risk of addressing only risks. CMAJ (2014) 0.75
Serious fungal infections in Canada. Eur J Clin Microbiol Infect Dis (2017) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Invasive aspergillosis. Clin Infect Dis (1998) 9.72
Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis (2006) 5.27
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis (2005) 3.96
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica (2006) 3.41
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis (2005) 2.59
Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med (1981) 2.07
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica (2009) 1.99
Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev (2008) 1.88
Incidence of nosocomial aspergillosis in patients with leukemia over a twenty-year period. Infect Control Hosp Epidemiol (1989) 1.62
Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol (2007) 1.60
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica (2001) 1.45
Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol (2000) 1.41
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2012) 1.35
Prophylaxis and aspergillosis--has the principle been proven? N Engl J Med (2007) 1.32
Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis (2008) 1.30
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother (2010) 1.28
Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect (2002) 1.28
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica (2011) 1.17
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents (2010) 1.15
Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. Clin Infect Dis (2007) 1.10
Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia (2005) 1.07
Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. Int J Mol Sci (2012) 1.04
Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica (2011) 1.02
Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol (2008) 1.00
Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect (2012) 1.00
Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol (2001) 0.95
Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med (2011) 0.92
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Eur J Med Res (2011) 0.91
Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol (2003) 0.91
Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis (2011) 0.89
Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol (1995) 0.87
Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol (2011) 0.84
Pharmacoeconomic assessment of therapy for invasive aspergillosis. Mycoses (2013) 0.84
Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis (2010) 0.84
Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole. J Am Pharm Assoc (2003) (2010) 0.81
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer (2010) 0.81
Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med Mycol (2010) 0.80
Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study. Mycoses (2011) 0.80
Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol (2012) 0.78
Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia. Mycoses (2010) 0.76
Possible fulminant toxicity by all-trans-retinoic acid in a patient with acute promyelocytic leukemia. Farm Hosp (2010) 0.76